Tivic Health Systems

Valion Bio, operating at tivichealth.com and trading on Nasdaq under the ticker VBIO, is a clinical-stage immunotherapeutics company built around Entolimod, a Toll-like Receptor 5 (TLR5) agonist intended to activate the innate immune system against radiation injury, infection and cellular stress. The lead indication is Acute Radiation Syndrome (ARS), pursued under the U.S. FDA's Animal Rule framework, a pathway used for medical countermeasures where human efficacy trials are not ethically feasible. Entolimod has received FDA Fast Track and Orphan Drug designations for ARS. The same molecule is being advanced into oncology supportive care for chemotherapy- and radiation-induced neutropenia, with immuno-oncology applications at an earlier stage. A second-generation follow-on compound, Entolasta, is in IND-enabling work for chronic indications.

The company describes three assets under a single innate-immunity thesis: Entolimod, the wholly owned contract development and manufacturing organization Velocity Bioworks, and a government-contracting pathway. Velocity Bioworks is a U.S.-based CDMO in San Antonio, Texas, that supports the company's own supply chain and also serves outside clinical-stage biotech clients. The government pathway involves engagement with BARDA, NIAID, DTRA and the Department of War, following prior federal contracts.

The company frames its near-term milestones over a 12- to 24-month horizon as BARDA engagement outcomes, initiation of a neutropenia trial, GMP manufacturing validation and regulatory milestones, and positions itself for institutional and informed investors.

Business model

The company combines drug development with owned manufacturing: Entolimod and the follow-on Entolasta are advanced through clinical and regulatory pathways, including U.S. government medical-countermeasure channels, while wholly owned CDMO subsidiary Velocity Bioworks provides internal biomanufacturing capacity and sells contract development and manufacturing services to third-party biotech clients.

Present revenue is generated by Velocity Bioworks, which earns independent commercial revenue from outside clinical-stage biotech customers for contract development and manufacturing services; the therapeutic programs are pre-commercial and have historically drawn on institutional and U.S. federal funding, including federal contracts.

Traction

The company reports that more than $140 million has been invested in the Entolimod program across institutional and U.S. government funding, that Entolimod has been administered to more than 300 humans in prior clinical studies, and that prior federal contracts total $35.6 million. Velocity Bioworks generates independent commercial revenue from outside biotech clients.

Latest developments

Entolasta, a second-generation follow-on to Entolimod, is in IND-enabling work for chronic indications. The company identifies upcoming catalysts over 12 to 24 months including BARDA engagement outcomes, neutropenia trial initiation, GMP manufacturing validation and regulatory milestones.